
Anja Moncsek

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2965452/publications.pdf Version: 2024-02-01



ANIA MONCSER

#	Article	IF	CITATIONS
1	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 557-588.	17.8	1,155
2	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature, 2021, 592, 450-456.	27.8	649
3	Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosisâ€4 score and aspartate aminotransferaseâ€platelet ratio index. Liver International, 2017, 37, 369-376.	3.9	207
4	Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. Journal of Hepatology, 2019, 70, 700-709.	3.7	112
5	The tumour microenvironment and immune milieu of cholangiocarcinoma. Liver International, 2019, 39, 63-78.	3.9	109
6	Targeting senescent cholangiocytes and activated fibroblasts with Bâ€cell lymphomaâ€extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2â^'/â^') mice. Hepatology, 2018, 67, 247-259.	7.3	99
7	The EBI2-oxysterol axis promotes the development of intestinal lymphoid structures and colitis. Mucosal Immunology, 2019, 12, 733-745.	6.0	40
8	Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis. Journal of Lipid Research, 2019, 60, 1270-1283.	4.2	37
9	Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland. Swiss Medical Weekly, 2018, 148, w14560.	1.6	10
10	A single nucleotide polymorphism in the gene for GPR183 increases its surface expression on blood lymphocytes of patients with inflammatory bowel disease. British Journal of Pharmacology, 2021, 178, 3157-3175.	5.4	9